Revolution Medicines (RVMD) Operating Leases (2020 - 2026)

Revolution Medicines' Operating Leases history runs 7 years deep, the most recent figure standing at $140.0 million for Q1 2026.

• In Q1 2026, Operating Leases rose 15.37% year-over-year to $140.0 million; the TTM figure through Mar 2026 stood at $140.0 million (up 15.37% YoY), while the FY2025 annual figure was $142.2 million, up 15.66% from the prior year.
• Operating Leases for Q1 2026 stood at $140.0 million, down from $142.2 million in the prior quarter.
• The five-year high for Operating Leases was $142.2 million in Q4 2025, with the low at $57.1 million in Q3 2023.
• The 5-year median for Operating Leases is $79.1 million (2024), against an average of $89.0 million.
• Peak annual rise in Operating Leases reached 116.88% in 2022, while the deepest fall reached 4.94% in 2022.
• Revolution Medicines' Operating Leases stood at $57.4 million in 2022, then jumped by 40.3% to $80.6 million in 2023, then jumped by 52.62% to $123.0 million in 2024, then climbed by 15.66% to $142.2 million in 2025, then retreated by 1.56% to $140.0 million in 2026.
• Business Quant data shows RVMD's Operating Leases at $140.0 million in Q1 2026, $142.2 million in Q4 2025, and $142.1 million in Q3 2025.